Extended Data Fig. 5. APRIL and sBCMA decrease the killing potency of BCMA TCE and to a lesser extent the potency of ISB 2001.
(a) Table summarizing average EC50 (pM) killing values in the absence or presence of soluble factors (sBCMA, APRIL and sCD38) for ISB 2001, teclistamab, EM801 and alnuctamab in KMS-12-BM cell line. (b) EC50 killing potency of ISB 2001, teclistamab, EM801 and alnuctamab against the KMS-12-BM cell line in the presence of sBCMA, APRIL or sCD38 alone. PBMC were used as effector cells at a 5:1 ratio.Log10(EC50) (n = 6 PBMC donors from 2 experiments) were compared using repeated measure ANOVA model and Tukey HSD comparison and statistical differences are shown only to compare ISB 2001 to TCEs for each soluble factors when statistically significant (P < 0.05).